Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) reported that on July 5, 2026, its Board Compensation Committee granted inducement equity awards under the company’s 2021 Employment Inducement Incentive Award Plan to three new employees, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards total 114,622 restricted stock units (RSUs), allocated among the three hires as a condition of commencing employment. According to Precision BioSciences, the RSUs vest in substantially equal annual installments over three years, on each of the first three anniversaries of the employees’ respective employment start dates, subject to continued service.
Precision BioSciences (Nasdaq: DTIL) announced its addition to the Russell 2000 Index, effective after the U.S. market close on June 26, 2026. Membership lasts one year and brings automatic inclusion in related growth and value style indexes.
The company is advancing two wholly owned clinical programs and reports a cash runway through 2028.
Precision BioSciences (Nasdaq: DTIL) reported new ELIMINATE-B trial data for PBGENE-HBV in chronic hepatitis B at EASL 2026. Liver biopsies showed a 1-log (10-fold) reduction in cccDNA-derived transcripts after two 0.4 mg/kg doses, with indels inactivating polymerase in the remaining <1% of cccDNA.
PBGENE-HBV achieved durable pgRNA loss in 100% of evaluable patients (n=6) and substantial HBsAg declines in all treated patients (n=15). Across 38 doses in 16 patients, no dose-limiting toxicities occurred; observed Grade 3 lab abnormalities and hypotension were reversible, with mitigation measures reducing severe events.
Precision BioSciences (Nasdaq: DTIL) will host an investor webcast on May 27, 2026, at 8:00 AM EDT. The event will feature Hepatitis B experts and company management discussing new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B.
The webcast follows late-breaking biopsy data presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. A replay and a separate news release with detailed clinical data will be available on the company’s investor website after the conference embargo lifts.
iECURE (NASDAQ:DTIL) reported preliminary results from the low-dose cohort of its OTC-HOPE trial of ECUR-506 in neonatal-onset OTC deficiency.
The first treated infant showed 18 months without HAEs and stopped standard care. Across three low-dose patients, annualized HAEs fell 57% and HACs 65%, with generally well-tolerated safety in seven dosed participants.
Precision BioSciences (Nasdaq: DTIL) reported new preclinical PBGENE-DMD data at the ASGCT 2026 meeting. Early-juvenile DMD mice showed up to 3x higher skeletal and 12x higher respiratory dystrophin restoration versus late-juvenile mice, with diaphragm up to 12% and intercostals up to 30%, supporting evaluation in boys aged 2–3 years within the Phase 1/2 FUNCTION-DMD trial.
iECURE (NASDAQ:DTIL) reported preliminary data from the ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency, covering 7 participants across three dose cohorts as of April 20, 2026.
71% (5/7) had no hyperammonemic crises (HACs) post-treatment and the annualized HAC rate fell about 52%, from ~3.12 to ~1.49 events per year. ECUR-506 was generally well tolerated, with no infusion-related reactions or thrombotic microangiopathy and no prophylactic immunosuppression. Asymptomatic Grade 2–3 transaminitis occurred in 5 of 7 participants and was controlled with reactive immunosuppression. One death from hypoxemic respiratory failure was assessed as unrelated to ECUR-506 and linked to underlying disease complications. These early data support continued evaluation of ECUR-506’s safety and clinical activity.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
Precision BioSciences (Nasdaq: DTIL) said it will publish first quarter 2026 financial results and provide a business update on May 5, 2026. The company is a clinical‑stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high‑unmet‑need diseases.
Precision BioSciences (Nasdaq: DTIL) activated Arkansas Children’s Hospital as the first clinical trial site and opened patient screening and enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study on April 29, 2026. PBGENE-DMD targets DMD mutations between exons 45 and 55 and will assess safety, tolerability, dystrophin expression, and functional outcomes in ambulatory patients.
Arkansas Children’s is a PPMD-certified Duchenne Care Center and an MDA Care Center; additional sites are being activated to expand enrollment.